Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note released on Sunday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 4.1 %

NASDAQ:LPCN opened at $4.54 on Friday. The company has a 50-day moving average of $4.77 and a 200-day moving average of $4.76. The firm has a market cap of $24.29 million, a price-to-earnings ratio of -5.97 and a beta of 1.23. Lipocine has a twelve month low of $3.20 and a twelve month high of $11.79.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.